Our manufacturing facility based out of Cuernavaca, Mexico is capable of handling small molecule APIs, Steroids and mPEG alcohol. The CDMO plant has a legacy of +15 years and is spread across 122,453 m2. The facility handles complex chemical synthesis and is designed to handle cryogenic processes. The installed production capacity per year is 3,300 tons and all operations are carried out in closed conditions.
The facility is inspected by: COFEPRIS US FDA KFDA EDQM Ministry of Industry and Trade of the Russian Federation MoH Romania
Other Locations
Why Aurigene Services?
18 years of experience
Experience gained from 100+ discovery programmes
World-class infrastructure
Track record of delivering 8+ IND candidates
Flexible working models
Quick turnaround time
Capabilities to apply multiple modalities
Seamless integration capabilities with Biology as well as CDMO services
Integrated project management
Expertise in various therapeutic modalities
Contact Us
Services
Aurigene Pharmaceutical Services Limited is a leading contract research, development and manufacturing organization (CDMO) providing end-to-end solutions. With a strong legacy of services in discovery, development and manufacturing we are ideally positioned to serve global pharma and specialty companies worldwide.
Resources
MAY 19, 2023
“Bathtub Chemistry” - Necessity and Aspects of Process Research
Medicine is an essential part of our life. Since ancient time human civilization has been tirelessly engaged to understand the cause and effect of a disease. Sometimes they win and many times they loss. But the story of their curiosity and enthusiasm is a never damping process. On the contrary it increases day by day, year after year.  ...
Read More
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization
Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contract development and manufacturing organizations (CDMOs) for collaborations as they seek more adaptable capacity and c...
Read More
How the re-designed synthesis of a complex carbohydrate can reduce cycle time
Project challenge: Complex carbohydrate chemistry involving a linear sequence of 10 chemical transformations, unstable intermediates and column chromatographic purications. Solution design: Process research and optimization was performed to develop a robust and scalable process which was implemented on commercial scale. Telescoping of reactions reduced the number...
Read More
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2023
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2005
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More -
Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications
2005
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.